Ticker brief

ZTS ZOETIS INC

Consumer, Non-cyclical · Pharmaceuticals

last close
$77.34
1 day
+3.1%
14 days
+4.8%
mkt cap
$31.4B
signals 14d
18
authors 14d
13
crowd 14d
+1.9σ
Options inteloptions-surface reads · latest available day per source
metricreadingcontext
IV — ATM 30d35% mid · 58 pctile own 1yIV/HV 0.85×
Skew — 25Δ RR 30d+0.010 91 pctile own 1ycalls bid vs puts (call skew rich)
Net dealer OI (NDOI)+0.67 elevated5-session Δ +0.07 (as of 2026-07-06)
OI alarmquietlast alarm 2026-06-05 (z=3.1)
Sentiment — last 14 days
daily mean sentiment, 2026-08-17 → 2026-08-26 · now +0.36 (−1 bearish … +1 bullish)
Who spoke13
authorgradetrader scoresignalsmean sent
@EchoAnalysisC-1.445+0.63
@KrisPatel99A+0.622+0.67
@PeloSwingC-0.751+0.50
@fiscal_aiB-0.371+0.35
@UTEX_ioC+0.611+0.25
@cfromhertzB-0.211+0.35
@FlowbyBobbyC·1+0.35
@OpenOutcrierC·1+0.40
@RichardWedekin1B+2.261+0.45
@0xtechquityB-1.741+0.50
@DJ_TaoC-1.201-0.25
@DimitryNakhlaA+0.841+0.00
@JerryCapA-1.721-0.30
Recent signals18of 18 in 14d — receipts included
date (PT)authorsentwhat they saidsince thenreceipt
2026-08-26@JerryCap-0.30Criticizes ZTS for repurchasing heavily above today's price while leaving limited authorization when shares are cheap.-0.2%
2026-08-26@DimitryNakhla+0.00Clarifies ZTS was merely an example, not one of the author's top stocks.-0.2%
2026-08-26@EchoAnalysis+0.75Continue buying ZTS here ahead of a breakout. — Says ZTS is near a breakout and the author remains happy buying.-0.2%
2026-08-26@KrisPatel99+0.65Calls ZTS a likely mean-reversion opportunity based on valuation, buybacks and insider buying.-0.2%
2026-08-26@KrisPatel99+0.70Buy ZTS as healthcare rotates higher and technicals improve — Says the technical setup is attractive enough to buy amid a healthcare rotation thesis.-0.2%
2026-08-25@DJ_Tao-0.25Calls META solid while expressing concern that ZTS must improve.+0.1%
2026-08-24@EchoAnalysis+0.05Broad watchlist cites moving averages, Fibonacci tests and buy zones without concrete author entry intent.+0.2%
2026-08-23@EchoAnalysis+0.90Author maintains a strong bullish ZTS view and cites a 423% Wave 3 target.-0.5%
2026-08-23@0xtechquity+0.50Calls the S&P 500 expensive and presents low-P/E stocks as potential market-beating picks.-0.5%
2026-08-23@RichardWedekin1+0.45Highlights Zoetis as having the highest gross, operating, net and free-cash-flow margins in the comparison.-0.5%
2026-08-22@EchoAnalysis+0.65Predicts a five-stock defensive basket will heavily outperform the market over coming years.-0.5%
2026-08-21@OpenOutcrier+0.40Recaps unusual call activity; output is capped at the first six tickers.-0.5%
2026-08-21@FlowbyBobby+0.35Reports $260K of whale buying in ZTS calls.-0.5%
2026-08-21@cfromhertz+0.35ZTS is emerging from a base and high-volatility value area while below its 200-day average.-0.5%
2026-08-19@UTEX_io+0.25Notes ZTS at an unusually low 11.4x EV/EBIT valuation for long-term holders.+0.9%
2026-08-19@fiscal_ai+0.35Reports Zoetis at its lowest recorded valuation with 11.4x EV/EBIT.+0.9%
2026-08-18@PeloSwing+0.50Reports FDA approval for ZTS's dog treatment while citing basing action and Burry ownership.+4.6%
2026-08-17@EchoAnalysis+0.80ZTS remains a buy while retesting the 0.786 Fibonacci level. — Explicitly maintains a buy call with a 470% Wave 3 target.+6.0%

“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.